Selective leishmanicidal effect of 1,3,4-thiadiazole derivatives and possible mechanism of action against Leishmania species

Experimental Parasitology

Volumn 121, Issue 4, 2009, Pages 323-330

  Poorrajab, Fatemeh ^a   Ardestani, Sussan K ^a   Foroumadi, Alireza ^b   Emami, Saeed ^c   Kariminia, Amina ^d   Behrouzi Fardmoghadam, Mina ^b   Shafiee, Abbas ^b  

^a UNIVERSITY OF TEHRAN   (Iran)

^b Tehran University of Medical Science   (Iran)

^c MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

DNA topoisomerases I and II; Inhibitory effects; Leishmania sp.; Selectivity Index; Toxicity assays

Indexed keywords

DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); THIADIAZOLE DERIVATIVE;

AMASTIGOTE; ARTICLE; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; HOST CELL; IC 50; LEISHMANIA; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

LEISHMANIA SP.;

EID: 85042599316     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2008.12.004     Document Type: Article

References (24)

1. Almeida-Amaral E.E., Belmont-Firpo R., Vannier-Santos M.A., and Meyer-Fernandes J.R. Leishmania amazonensis: Characterization of an ecto-phosphatase activity. Exp. Parasitol. 114 (2006) 334-340
2. Balana-Fouce R., Redondo C.M., Perez-Pertejo Y., Diaz-Gonzalez R., and Reguera R.M. Targeting atypical trypanosomatid DNA topoisomerase I. Drug Discov. Today 11 15 (2006) 733-740
3. Behrouzi-Fardmoghadam M., Poorrajab F., Ardestani S.K., Emami S., Shafiee A., and Foroumadi A. Synthesis and in vitro anti-leishmanial activity of 1-[5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-yl]- and 1-[5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazol-2-yl]-4-aroylpiperazines. Bioorg. Med. Chem. 16 (2008) 4509-4515
4. Berkelhammer G., and Asato G. 2-Amino-5-(1-methyl-5-nitro-2-imidazolyl)-1,3,4-thiadiazole: a new antimicrobial agent. Science 1162 (1968) 1146
5. Bringaud F., Riviere L., and Coustou V. Energy metabolism of trypanosomatids: Adaptation to available carbon sources. Mol. Biochem. Parasitol. 149 (2006) 1-9
6. Bailly C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr. Med. Chem. 7 (2000) 39-58
7. Croft S.L., Sundar S., and Fairlamb A.H. Drug resistance in Leishmaniasis. Clin. Microbiol. Rev. 19 1 (2006) 487-492
8. Das A., Dasgupta A., Sengupta T., and Majumder H.K. Topoisomerases of kinetoplastid parasites as potential chemotherapeutic targets. Trends Parasitol. 20 8 (2004) 381-388
9. Das B.B., Sengupta T., Ganguly A., and Majumder H.K. Topoisomerases of kinetoplastid parasites. Mol. Microbiol. 10 (2006) 1-11
10. Dutta A., Bandyopadhyay S., Mandal C., and Chatterjee M. Development of a modified MTT assay for screening antimonial resistantfield isolates of Indian visceral leishmaniasis. Parasitol. Int. 54 (2005) 110-122
11. Filardi L.S., and Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R. Soc. Trop. Med. Hyg. 81 (1987) 755-759
12. Foroumadi A., Emami S., Pournourmohammadi S., Kharazmi A., and Shafiee A. Synthesis and in vitro leishmanicidal activity of 2-(1-methyl-5-nitro-1H-imidazol-2-yl)-5-substituted-1,3,4-thiadiazole derivatives. Eur. J. Med. Chem. 40 (2005) 1346-1350
13. Foroumadi A., Pournourmohammadi S., Soltani F., Rezaee MA., Dabiri S., Kharazmi A., and Shafiee A. Synthesis and in vitro leishmanicidal activity of 2-(5-nitro-2-furyl) and 2-(5-nitro-2-thienyl)-5-substituted-1,3,4-thiadiazoles. Bioorg. Med. Chem. Lett. 15 (2005) 1983-1985
14. Guillon J., Forfar I., Mamani-Matsuda M., Desplat V., Saliege M., Thiolat D., Massip S., Tabourier A., Leger J.M., Dufaure B., Haumont G., Jarry C., and Mossalayi D. Synthesis, analytical behavior and biological evaluation of new 4-substituted pyrrolo(1,2-a)quinoxalines as antileishmanial agents. Bioorg. Med. Chem. 15 (2007) 194-210
15. Jean-Moreno V., Rojas R., Goyeneche D., Coombs G.H., and Walker J. Leishmania donovani: Differential activities of classical topoisomerase inhibitors and antileishmanials against parasite and host cells at the level of DNA topoisomerase I and in cytotoxicity assays. Exp. Parasitol. 112 (2006) 21-30
16. McClendona A.K., and Osheroff N. DNA topoisomerase II, genotoxicity, and cancer. Mutat. Res. 623 (2007) 83-97
17. Nascimento M., Zhang W.W., Ghosh A., Houston D.R., Berghuis A.M., Olivier M., and Matlashewski G. Identification and characterization of a protein-tyrosine phosphatase in Leishmania, involvement in virulence. J. Biol. Chem. 281 47 (2006) 36257-36268
18. Poorrajab, F., Ardestani, S.K., Emami, S., Behrouzi-Fardmoghadam, M., Shafiee, A., Foroumadi, A., 2008. Nitroimidazolyl-1,3,4-thiadiazole-based anti-leishmanial agents: Synthesis and in vitro biological evaluation. Eur. J. Med. Chem. doi:10.1016/j.ejmech.2008.03.039.
19. Reguera R.M., Perez-Pertejo Y., Redondo C.M., az-Gonzalez R., and Balana-Fouce R. Type I DNA topoisomerase from protozoan pathogens as a potential target for anti-tumoral drugs. Medicina 67 6 (2007) 747-757
20. Reguera R.M., Redondo C.M., Gutierrez de P.R., Perez-Pertejo Y., and Balana-Fouce R. DNA topoisomerase I from parasite protozoa: A potential target for chemotherapy. Biochim. Biophys. Acta 1759 (2006) 117-131
21. Shakarian A.M., Joshi M.B., Yamage M., Ellis S.L., Debrabant A., and Dwyer D.M. Members of a unique histidine acid phosphatase family are conserved amongst a group of primitive eukaryotic human pathogens. Mol. Cell Biochem. 245 (2003) 31-41
22. Tanaka A.K., Valero V.B., Takahashi H.K., and Straus A.H. Inhibition of Leishmania (Leishmania) amazonensis growth and infectivity by aureobasidin A. J. Antimicrob. Chemother. 59 (2007) 487-492
23. Viard T., Bouthier C., et al. Type I topoisomerases: A simple puzzle?. Biochimie 89 (2007) 456-467
24. Walker J., and Saravia N.G. Inhibition of Leishmania Donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerase I and II by antimonial drugs and classical anti-topoisomerase agents. J. parasitol. 90 56 (2004) 1155-1162